BioProcess International Europe is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Dan Adams
Co-Founder and Executive Chairman at NextWaveBio


Dan Adams is Co-Founder and Executive Chairman of NextWaveBio, a new company that is developing the next generation of safer, more affordable medicines. Previously he was CEO and then Executive Chairman of Protein Sciences Corporation, a leader in developing vaccines using its proprietary baculovirus expression vector (BEST) system. The US FDA licensed its lead vaccine, Flublok®, the first recombinant influenza vaccine, in January 2013, extended the age range in 2014 and approved the quadrivalent formulation in 2018. Flublok was also licensed in Mexico in 2016. The Company had a value of less than $2 million in 1996 and in 2017 it was acquired by Sanofi Pasteur for about $750 million. Previously Dan founded and managed several biotechnology companies that achieved a combined value of in excess of $70 billion. He co-founded Biogen in 1976 and was its first CEO; founded and was CEO of Advanced Genetic Sciences Inc., the first plant biotechnology company (Biogen and AGS were taken public in the 1980s), founded Plant Genetic Systems, the first European agricultural biotechnology company, and served as a managing director and chairman of the management committee (PGS was acquired by Agrivo for $750 million) and founded and was CEO of Allerx Inc. in 1999 - now a boutique company.

Dan Adams's Network

Agenda Sessions

  • Chairperson's Opening Remarks

  • Neoantigen-based personalized cancer vaccines: the promise is enormous but so is the cost that at current levels could bankrupt even developed nations’ economies